This application note presents a groundbreaking approach to addressing the challenges of identifying conserved, neutralizing epitopes for effective antibody therapeutics against emerging coronavirus variants. Leveraging multiplexed antigen screening and single-cell immune profiling technology, over 9,000 fully human CoV-specific antibodies were identified, paving the way for potential pan-coronavirus vaccine candidates. The manuscript also introduces Twist High Throughput Antibody (HT IgG) production, a gene-to-protein workflow designed to overcome the bottleneck of antibody synthesis, expression, and purification at scale, enabling rapid screening of hundreds or thousands of leads for biophysical and pharmacokinetic properties.

This application note presents a groundbreaking approach to addressing the challenges of identifying conserved, neutralizing epitopes for effective antibody therapeutics against emerging coronavirus variants. Leveraging multiplexed antigen screening and single-cell immune profiling technology, over 9,000 fully human CoV-specific antibodies were identified, paving the way for potential pan-coronavirus vaccine candidates. The manuscript also introduces Twist High Throughput Antibody (HT IgG) production, a gene-to-protein workflow designed to overcome the bottleneck of antibody synthesis, expression, and purification at scale, enabling rapid screening of hundreds or thousands of leads for biophysical and pharmacokinetic properties.